Omnicare Reaches New 52-Week High (OCR)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Omnicare (NYSE: OCR) hit a new 52-week high Wednesday as it is currently trading at $38.64, above its previous 52-week high of $38.63 with 100,814 shares traded as of 11:10 a.m. ET. Average volume has been 1.1 million shares over the past 30 days.

Omnicare has a market cap of $4.24 billion and is part of the services sector and wholesale industry. Shares are up 6.1% year to date as of the close of trading on Tuesday.

Omnicare, Inc. operates as a healthcare services company that specializes in the management of pharmaceutical care in the United States and Canada. The company has a P/E ratio of 21.4, above the S&P 500 P/E ratio of 17.7.

• EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Omnicare as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows low profit margins. You can view the full Omnicare Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.